Introduction:
Thermo Fisher Scientific has opened a new clinical and commercial ultra-cold GMP facility in Bleiswijk, The Netherlands, to support the development of advanced therapies. The facility offers tailored end-to-end support for high-value therapies, including cell and gene therapies, biologics, antibodies, and vaccines, throughout the clinical supply chain. It provides services such as storage, packaging, labeling, distribution, and clinical QP release.
- The new facility in the Netherlands aims to accelerate the development of advanced therapies by providing tailored support throughout the clinical supply chain.
- It offers end-to-end services for high-value therapies, including storage, packaging, labeling, distribution, and clinical QP release.
- The facility is strategically located outside of Amsterdam and provides services for cell and gene therapy products from development to commercialization.
- Thermo Fisher Scientific is committed to sustainability and operates the facility using eco-friendly technologies such as solar power, gas-free operations, and heat recovery.
- The facility enables customers to meet clinical trial requirements regardless of scale or phase and supports both new and established biotech and pharmaceutical companies.
Conclusion:
The opening of Thermo Fisher Scientific’s new ultra-cold facility in the Netherlands enhances the company’s capabilities in supporting the development of advanced therapies. With its end-to-end services and commitment to sustainability, the facility can contribute to the acceleration of clinical trials and the production of innovative therapies. This expansion of Thermo Fisher Scientific’s clinical trial network in Europe will benefit both new and established biotech and pharmaceutical companies in their quest to develop high-value therapies.
